Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved zilurgisertib (Atebrioz), a once-daily pill by Mirum Pharmaceuticals, for fibrodysplasia ossificans progressiva (FOP) — a rare condition where soft tissues gradually turn to bone. Approved for patients 12 and older, it works by blocking the overactive ALK2 protein that drives abnormal bone growth. With only ~300 patients in the US, it's a major milestone for an underserved population.
The FDA has approved zilurgisertib (Atebrioz), a once-daily oral pill from Mirum Pharmaceuticals, for fibrodysplasia ossificans progressiva (FOP) — an extremely rare and debilitating condition in which muscles, tendons, and ligaments progressively turn into bone, severely limiting movement. The drug is approved for patients aged 12 and older and works by blocking ALK2, a protein that is abnormally active in most FOP patients and drives bone formation outside the skeleton.
The approval was based on a 63-patient clinical trial in which Atebrioz significantly reduced new bone formation compared to placebo at week 24. Mirum plans to launch the drug in October, with pricing to be announced at launch. Analysts estimate it could cost around $750,000 annually and generate ~$150 million in peak global sales. Its oral convenience and strong efficacy profile could make it a preferred choice over existing therapies — Ipsen's Sohonos and Regeneron's Pasatru infusion.
By the Numbers:
Why it matters: FOP is one of the rarest and most disabling conditions known, with very few treatment options. Atebrioz's oral dosing and strong efficacy profile offer a meaningful new option for a small but profoundly affected patient community.
